Wells Fargo analyst Tiago Fauth raised the firm’s price target on PTC Therapeutics (PTCT) to $93 from $73 and keeps an Overweight rating on the shares. The firm notes the PKU launch is off to a strong start, and without stocking this represents organic uptake. Wells thinks persistence, and degree of switching will be key. FDA meeting on votoplam could be a sleepy catalyst, the firm adds.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $68 from $46 at Barclays
- PTC Therapeutics price target raised to $75 from $50 at Citi
- PTC Therapeutics: Strong Market Position and Growth Potential Drive Buy Rating
- PTC Therapeutics: Balancing Sephience Success with DMD Challenges and Strategic Shifts
- PTC Therapeutics Reports Strong Q3 2025 Results